Category: CT071
-
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 By Investing.com
•
Shanghai, June 15, 2024 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (ticker symbol: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematological malignancies and solid tumors, announces that preliminary results from the ongoing first-in-human study of CT071 have been presented at the conference. The twenty-ninth annual…